淋病治療薬の市場規模、シェア、成長分析、薬剤の種類別、治療の種類別、投与経路別、地域別 - 産業予測 2025～2032年

淋病治療薬の世界市場規模は、2023年に11億2,000万米ドルと評価され、2024年の11億6,000万米ドルから2032年には15億9,000万米ドルに成長し、予測期間（2025年～2032年）のCAGRは4.0％で成長する見通しです。

淋病治療薬市場は、抗生物質耐性を持つ淋菌の蔓延が増加し、世界各国政府が研究開発費をより多く割り当て、疾病監視の取り組みを強化するようになったため、勢いを増しています。公衆衛生意識の高まり、診断能力の向上、医療従事者のSTIに関する知識の向上が、革新的な治療ソリューションに対する需要を促進しています。製薬セクターは、バクテリオファージ療法や抗菌ペプチドのような従来とは異なるアプローチを模索しているが、成長は大きなハードルに直面しています。これには、抗菌薬耐性による治療選択肢の制限、STI治療薬に対する商業的インセンティブの弱さ、規制上の課題、臨床試験期間の長期化などが含まれます。さらに、STIを取り巻く社会的偏見が、特に中低所得国における診断と治療の妨げとなっており、ヘルスケアへのアクセス格差につながり、市場の可能性を制限しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• 規制分析
• 特許分析

淋病治療薬市場規模：薬剤の種類別& CAGR（2025-2032）

• 市場概要
• マクロライド系抗生物質（アジスロマイシン）
• 第三世代セファロスポリン
• テトラサイクリン系抗生物質（ドキシサイクリン）
• フルオロキノロン系抗生物質（ゲミフロキサシン）
• アミノグリコシド（ゲンタマイシン）
• アミノシクリトール（スペクチノマイシン）

淋病治療薬市場規模：治療の種類別& CAGR（2025-2032）

• 市場概要
• モノセラピー
• デュアルセラピー

淋病治療薬市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 筋肉内

淋病治療薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

淋病治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• GlaxoSmithKline plc.
• Merck & Co., Inc.
• Pfizer Inc
• AstraZeneca
• Hologic, Inc.
• Danaher
• Abbott
• Becton Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• Lupin Pharmaceuticals, Inc.
• Evofem Biosciences Inc
• SummitTherapeutics
• TherapyX

結論と提言

Global Gonorrhea Therapeutics Market size was valued at USD 1.12 billion in 2023 and is poised to grow from USD 1.16 billion in 2024 to USD 1.59 billion by 2032, growing at a CAGR of 4.0% during the forecast period (2025-2032).

The Gonorrhea Therapeutics Market is gaining momentum due to the rising prevalence of antibiotic-resistant Neisseria gonorrhoeae strains, prompting global governments to allocate more R&D funding and enhance disease monitoring efforts. Increased public health awareness, improved diagnostic capabilities, and heightened knowledge among healthcare providers of STIs are driving demand for innovative treatment solutions. The pharmaceutical sector is exploring non-conventional approaches like bacteriophage therapy and antimicrobial peptides, but growth faces substantial hurdles. These include limited treatment options due to antimicrobial resistance, weak commercial incentives for STI therapeutics, regulatory challenges, and prolonged clinical trial timelines. Furthermore, social stigma surrounding STIs hampers diagnosis and treatment, particularly in low- and middle-income nations, leading to disparities in healthcare access and limiting market potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gonorrhea Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gonorrhea Therapeutics Market Segments Analysis

Global Gonorrhea Therapeutics Market is segmented by Drug Type, Therapy Type, Route of Administration, Distribution channel and region. Based on Drug Type, the market is segmented into Macrolide Antibiotics (Azithromycin), Third-Generation Cephalosporins, Tetracycline Antibiotics (Doxycycline), Fluoroquinolone Antibiotics (Gemifloxacin), Aminoglycoside (Gentamicin) and Aminocyclitol (Spectinomycin). Based on Therapy Type, the market is segmented into Mono Therapy and Dual Therapy. Based on Route of Administration, the market is segmented into Oral and Intramuscular. Based on Distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gonorrhea Therapeutics Market

The rising global incidence of gonorrhea is a key driver fueling growth in the Gonorrhea Therapeutics market. According to the World Health Organization, over 82 million new cases are reported each year, primarily due to unprotected sexual practices, limited knowledge of sexual health, and inadequate sexual education. The emergence of drug-resistant strains of the bacteria poses significant challenges for healthcare management, necessitating more effective therapeutic options. Additionally, increased urbanization and limited access to healthcare services in developing regions contribute to the escalating disease burden, prompting health organizations to invest in the development of advanced treatments, thereby elevating the overall demand for therapeutic solutions.

Restraints in the Global Gonorrhea Therapeutics Market

A significant challenge facing the global gonorrhea therapeutics market is the rapid emergence of antibiotic-resistant strains of Neisseria gonorrhoeae, which significantly undermines the effectiveness of current treatment options. Frontline antibiotics, such as cephalosporins and fluoroquinolones, are experiencing reduced efficacy due to resistance, resulting in fewer available therapies. This growing resistance not only prolongs treatment times but also escalates healthcare expenditures and raises the risk of transmission. In addition, the development of new antibiotics is fraught with complexities, high costs, and uncertain returns on investment. The dynamic nature of resistance patterns necessitates ongoing surveillance and timely drug modifications, complicating the reliable delivery of treatments and curtailing the market's dependence on established therapies.

Market Trends of the Global Gonorrhea Therapeutics Market

The Global Gonorrhea Therapeutics market is poised for growth in the short term, driven by heightened awareness of sexually transmitted infections (STIs) and the implementation of government-led screening initiatives that facilitate higher diagnosis rates. This rise in diagnoses is likely to spur demand for effective therapeutics, particularly as healthcare providers increasingly adopt dual therapy regimens, such as ceftriaxone combined with azithromycin, as the clinical standard of care. However, emerging concerns regarding antibiotic resistance are influencing treatment protocols and may prompt further innovation in therapeutic options. This landscape underscores the need for ongoing surveillance and adaptive strategies in managing gonorrhea effectively.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Regulatory Analysis
• Patent Analysis

Global Gonorrhea Therapeutics Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Macrolide Antibiotics (Azithromycin)
• Third-Generation Cephalosporins
• Tetracycline Antibiotics (Doxycycline)
• Fluoroquinolone Antibiotics (Gemifloxacin)
• Aminoglycoside (Gentamicin)
• Aminocyclitol (Spectinomycin)

Global Gonorrhea Therapeutics Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Mono Therapy
• Dual Therapy

Global Gonorrhea Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intramuscular

Global Gonorrhea Therapeutics Market Size by Distribution channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Gonorrhea Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Type, Therapy Type, Route of Administration, Distribution channel)
  • US
  • Canada
• Europe (Drug Type, Therapy Type, Route of Administration, Distribution channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Therapy Type, Route of Administration, Distribution channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Therapy Type, Route of Administration, Distribution channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Therapy Type, Route of Administration, Distribution channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline plc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evofem Biosciences Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SummitTherapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TherapyX
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations